REGENXBIO (RGNX) Competitors

$10.30 +0.22 (+2.17%)

As of 02:26 PM Eastern

RGNX vs. SRPT, SION, TRVI, BHC, and STOK

Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Sarepta Therapeutics (SRPT), Sionna Therapeutics (SION), Trevi Therapeutics (TRVI), Bausch Health Cos (BHC), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

How does REGENXBIO compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Sarepta Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Sarepta Therapeutics presently has a consensus target price of $27.71, suggesting a potential upside of 43.42%. REGENXBIO has a consensus target price of $27.50, suggesting a potential upside of 167.02%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

REGENXBIO has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.93	-$713.41M	-$0.96	N/A
REGENXBIO	$170.44M	3.12	-$193.88M	-$3.76	N/A

In the previous week, Sarepta Therapeutics had 18 more articles in the media than REGENXBIO. MarketBeat recorded 21 mentions for Sarepta Therapeutics and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.62 beat Sarepta Therapeutics' score of 0.39 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a net margin of -2.94% compared to REGENXBIO's net margin of -113.75%. Sarepta Therapeutics' return on equity of 7.56% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
REGENXBIO	-113.75%	-103.12%	-37.83%

Summary

REGENXBIO beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Sionna Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -113.75%. Sionna Therapeutics' return on equity of -22.87% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-22.87%	-21.71%
REGENXBIO	-113.75%	-103.12%	-37.83%

Sionna Therapeutics has higher earnings, but lower revenue than REGENXBIO. Sionna Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.95	N/A
REGENXBIO	$170.44M	3.12	-$193.88M	-$3.76	N/A

In the previous week, Sionna Therapeutics had 20 more articles in the media than REGENXBIO. MarketBeat recorded 23 mentions for Sionna Therapeutics and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.62 beat Sionna Therapeutics' score of 0.21 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	5 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics presently has a consensus target price of $53.00, suggesting a potential upside of 28.93%. REGENXBIO has a consensus target price of $27.50, suggesting a potential upside of 167.02%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

88.1% of REGENXBIO shares are owned by institutional investors. 3.9% of Sionna Therapeutics shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Sionna Therapeutics beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Trevi Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Trevi Therapeutics presently has a consensus target price of $22.90, suggesting a potential upside of 54.99%. REGENXBIO has a consensus target price of $27.50, suggesting a potential upside of 167.02%. Given REGENXBIO's higher possible upside, analysts clearly believe REGENXBIO is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Trevi Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -113.75%. Trevi Therapeutics' return on equity of -23.94% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.94%	-22.76%
REGENXBIO	-113.75%	-103.12%	-37.83%

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Trevi Therapeutics had 26 more articles in the media than REGENXBIO. MarketBeat recorded 29 mentions for Trevi Therapeutics and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.62 beat Trevi Therapeutics' score of 0.33 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics has higher earnings, but lower revenue than REGENXBIO. Trevi Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
REGENXBIO	$170.44M	3.12	-$193.88M	-$3.76	N/A

Summary

Trevi Therapeutics beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 47.74%. REGENXBIO has a consensus price target of $27.50, indicating a potential upside of 167.02%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts clearly believe REGENXBIO is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Bausch Health Cos has a net margin of -11.47% compared to REGENXBIO's net margin of -113.75%. REGENXBIO's return on equity of -103.12% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
REGENXBIO	-113.75%	-103.12%	-37.83%

Bausch Health Cos has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.20	$157M	-$3.24	N/A
REGENXBIO	$170.44M	3.12	-$193.88M	-$3.76	N/A

In the previous week, REGENXBIO had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 3 mentions for REGENXBIO and 1 mentions for Bausch Health Cos. REGENXBIO's average media sentiment score of 0.62 beat Bausch Health Cos' score of 0.50 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

REGENXBIO beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Stoke Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than REGENXBIO. Stoke Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.88	-$6.89M	-$2.81	N/A
REGENXBIO	$170.44M	3.12	-$193.88M	-$3.76	N/A

88.1% of REGENXBIO shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

REGENXBIO has a net margin of -113.75% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -51.16% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-51.16%	-43.78%
REGENXBIO	-113.75%	-103.12%	-37.83%

Stoke Therapeutics presently has a consensus price target of $41.83, indicating a potential upside of 29.82%. REGENXBIO has a consensus price target of $27.50, indicating a potential upside of 167.02%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Stoke Therapeutics had 12 more articles in the media than REGENXBIO. MarketBeat recorded 15 mentions for Stoke Therapeutics and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.62 beat Stoke Therapeutics' score of 0.42 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Stoke Therapeutics beats REGENXBIO on 10 of the 17 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$529.67M	$3.41B	$6.28B	$12.10B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-2.73	15.30	20.55	25.41
Price / Sales	3.12	303.37	545.88	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	5.07	6.85	9.62	6.65
Net Income	-$193.88M	$24.11M	$3.55B	$333.40M
7 Day Performance	11.70%	-1.57%	-0.36%	-0.58%
1 Month Performance	17.03%	3.83%	5.99%	7.66%
1 Year Performance	29.22%	71.34%	38.59%	35.36%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	2.46 of 5 stars	$10.30 +2.2%	$27.50 +167.0%	+34.0%	$529.67M	$170.44M	N/A	370	Positive News
SRPT Sarepta Therapeutics	3.645 of 5 stars	$20.07 +0.6%	$27.71 +38.1%	-46.5%	$2.12B	$2.20B	N/A	1,372	Earnings Report
SION Sionna Therapeutics	2.5293 of 5 stars	$46.76 +5.7%	$53.00 +13.3%	+273.0%	$2.11B	N/A	N/A	35	Trending News Earnings Report Insider Trade
TRVI Trevi Therapeutics	3.3263 of 5 stars	$14.61 +0.8%	$22.90 +56.7%	+125.5%	$2.08B	N/A	N/A	20	Earnings Report Analyst Downgrade
BHC Bausch Health Cos	2.3063 of 5 stars	$5.56 -3.4%	$8.00 +44.0%	+17.7%	$2.07B	$10.53B	N/A	20,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. SRPT, SION, TRVI, BHC, and STOK

How does REGENXBIO compare to Sarepta Therapeutics?

Summary

How does REGENXBIO compare to Sionna Therapeutics?

Summary

How does REGENXBIO compare to Trevi Therapeutics?

Summary

How does REGENXBIO compare to Bausch Health Cos?

Summary

How does REGENXBIO compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. SRPT, SION, TRVI, BHC, and STOK

How does REGENXBIO compare to Sarepta Therapeutics?

Which has more risk & volatility, SRPT or RGNX?

Do analysts recommend SRPT or RGNX?

Which has higher earnings and valuation, SRPT or RGNX?

Does the media favor SRPT or RGNX?

Do institutionals and insiders hold more shares of SRPT or RGNX?

Is SRPT or RGNX more profitable?

Summary

How does REGENXBIO compare to Sionna Therapeutics?

Which has more volatility and risk, SION or RGNX?

Is SION or RGNX more profitable?

Which has stronger earnings & valuation, SION or RGNX?

Does the media favor SION or RGNX?

Do analysts recommend SION or RGNX?

Do insiders & institutionals hold more shares of SION or RGNX?

Summary

How does REGENXBIO compare to Trevi Therapeutics?

Which has more risk and volatility, TRVI or RGNX?

Do analysts prefer TRVI or RGNX?

Is TRVI or RGNX more profitable?

Do institutionals & insiders hold more shares of TRVI or RGNX?

Does the media refer more to TRVI or RGNX?

Which has preferable earnings and valuation, TRVI or RGNX?

Summary

How does REGENXBIO compare to Bausch Health Cos?

Which has more risk & volatility, BHC or RGNX?

Do institutionals and insiders believe in BHC or RGNX?

Do analysts recommend BHC or RGNX?

Is BHC or RGNX more profitable?

Which has higher valuation and earnings, BHC or RGNX?

Does the media favor BHC or RGNX?

Summary

How does REGENXBIO compare to Stoke Therapeutics?

Which has more volatility and risk, STOK or RGNX?

Which has stronger earnings and valuation, STOK or RGNX?

Do insiders & institutionals believe in STOK or RGNX?

Is STOK or RGNX more profitable?

Do analysts recommend STOK or RGNX?

Does the media favor STOK or RGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools